NCM·Healthcare·$713M·#264 / 520 in Healthcare
LXRX Lexicon Pharmaceuticals, Inc.
43SPECULATIVE
CATEGORY BREAKDOWN
GROWTH84
QUALITY60
STABILITY23
VALUATION30
GOVERNANCE8
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+60.2%
84
> 50% strong
Gross Margin
Revenue retained after direct costs
99.4%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
10
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
58.4%
47
< 25% strong
Price / Sales
Market cap relative to trailing revenue
14.3x
30
< 3x strong
Rule of 40
Growth rate plus operating margin
-38
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.0%
8
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+21.5%
9
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE LXRX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when LXRX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.